ProShare Advisors’s Arbutus Biopharma ABUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $132K | Sell |
27,536
-3,015
| -10% | -$13.2K | ﹤0.01% | 1735 |
|
|
2026
Q1 | $137K | Sell |
30,551
-5,610
| -16% | -$24.5K | ﹤0.01% | 1664 |
|
|
2025
Q4 | $174K | Buy |
36,161
+3,446
| +11% | +$15.5K | ﹤0.01% | 1763 |
|
|
2025
Q3 | $149K | Sell |
32,715
-5,480
| -14% | -$20.1K | ﹤0.01% | 1772 |
|
|
2025
Q2 | $118K | Sell |
38,195
-1,977
| -5% | -$6.57K | ﹤0.01% | 1848 |
|
|
2025
Q1 | $140K | Sell |
40,172
-9,949
| -20% | -$33.2K | ﹤0.01% | 1773 |
|
|
2024
Q4 | $164K | Buy |
50,121
+11,359
| +29% | +$41.8K | ﹤0.01% | 1946 |
|
|
2024
Q3 | $149K | Buy |
38,762
+10,144
| +35% | +$38.9K | ﹤0.01% | 1804 |
|
|
2024
Q2 | $88.4K | Sell |
28,618
-5,897
| -17% | -$17.7K | ﹤0.01% | 1681 |
|
|
2024
Q1 | $89K | Buy |
34,515
+2,829
| +9% | +$7.33K | ﹤0.01% | 1840 |
|
|
2023
Q4 | $79.2K | Buy |
31,686
+4,516
| +17% | +$8.84K | ﹤0.01% | 1811 |
|
|
2023
Q3 | $55.2K | Buy |
27,170
+188
| +0.7% | +$394 | ﹤0.01% | 1709 |
|
|
2023
Q2 | $62.1K | Buy |
26,982
+2,763
| +11% | +$7.19K | ﹤0.01% | 1752 |
|
|
2023
Q1 | $73.4K | Sell |
24,219
-3,339
| -12% | -$9.42K | ﹤0.01% | 1637 |
|
|
2022
Q4 | $64.2K | Buy |
27,558
+3,043
| +12% | +$7.28K | ﹤0.01% | 1711 |
|
|
2022
Q3 | $47K | Buy |
24,515
+802
| +3% | +$1.89K | ﹤0.01% | 1666 |
|
|
2022
Q2 | $64K | Sell |
23,713
-7,367
| -24% | -$18.9K | ﹤0.01% | 1670 |
|
|
2022
Q1 | $93K | Sell |
31,080
-5,519
| -15% | -$16.9K | ﹤0.01% | 2046 |
|
|
2021
Q4 | $142K | Buy |
36,599
+5,122
| +16% | +$19.9K | ﹤0.01% | 2139 |
|
|
2021
Q3 | $135K | Sell |
31,477
-6,103
| -16% | -$20.3K | ﹤0.01% | 1864 |
|
|
2021
Q2 | $114K | Buy |
37,580
+25,830
| +220% | +$80K | ﹤0.01% | 2277 |
|
|
2021
Q1 | $39K | Sell |
11,750
-1,354
| -10% | -$5.22K | ﹤0.01% | 2238 |
|
|
2020
Q4 | $47K | Buy |
+13,104
| New | +$45.9K | ﹤0.01% | 2048 |
|
|
2019
Q4 | – | Sell |
-15,394
| Closed | -$23K | – | 1788 |
|
|
2019
Q3 | $23K | Sell |
15,394
-4,948
| -24% | -$8.53K | ﹤0.01% | 1640 |
|
|
2019
Q2 | $42K | Sell |
20,342
-2,340
| -10% | -$5.99K | ﹤0.01% | 1580 |
|
|
2019
Q1 | $81K | Buy |
22,682
+161
| +0.7% | +$618 | ﹤0.01% | 1587 |
|
|
2018
Q4 | $86K | Sell |
22,521
-4,390
| -16% | -$21.6K | ﹤0.01% | 1489 |
|
|
2018
Q3 | $254K | Sell |
26,911
-924
| -3% | -$9.18K | ﹤0.01% | 1454 |
|
|
2018
Q2 | $203K | Buy |
27,835
+2,382
| +9% | +$14.2K | ﹤0.01% | 1600 |
|
|
2018
Q1 | $127K | Sell |
25,453
-4,207
| -14% | -$22.3K | ﹤0.01% | 1615 |
|
|
2017
Q4 | $150K | Buy |
+29,660
| New | +$174K | ﹤0.01% | 1689 |
|
Other funds holding ABUS
TSC
WCM
RCMNY
ProShare Advisors's ABUS Position: Q2 2026 in Review
ProShare Advisors reduced its Arbutus Biopharma (ABUS) stake by 9.9% in Q2 2026, selling an estimated $13.2K and leaving 27,536 shares worth $132K. The position accounts for ﹤0.01% of the portfolio, ranked #1735.
ProShare Advisors first reported a position in ABUS in Q4 2017 and has held it in 31 quarters since. The position peaked at $254K in Q3 2018. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.
- ProShare Advisors held 27,536 shares of Arbutus Biopharma worth $132K as of Q2 2026.
- ProShare Advisors sold 3,015 Arbutus Biopharma shares in Q2 2026, an estimated $13.2K.
- Arbutus Biopharma made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1735 holding.
- ProShare Advisors first reported a position in Arbutus Biopharma in Q4 2017 and has held it in 31 quarters since.
- ProShare Advisors's Arbutus Biopharma position peaked at $254K in Q3 2018.
- 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.
Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.